We report on the use of interferon-alpha ( @entity13089 ) and high-dose non-specific intravenous immunoglobulin (IVIg) in 2 @entity1 (a 60-yr-old female and a 65-yr-old male) who developed @entity1071 ( @entity1071 ) 2 and 8 months after heart and liver transplantation, respectively. Both @entity1 had received immunosuppression with ATG, CsA, @entity500 , and @entity229 . The first @entity1 did not receive additional immunosuppression with biological agents. The second @entity1 developed 3 @entity134 -resistant acute rejection episodes requiring OKT3 (cumulative dose 100 mg) and ATG (cumulative dose 3450 mg). The first @entity1 presented with nodules involving the liver, spleen, lungs and nasophar, ynx. The second @entity1 presented with subcutaneous and liver nodules, as well as pert-portal and para-aortic lymphadenopathies. The histological diagnosis was diffuse B-cell @entity1071 in both @entity1 . Despite reduction of immunosuppression, a progression of lesions was observed in both @entity1 over 5 months and 2 months, respectively. The first @entity1 received @entity13089 (2 x 10(6) IU, s.c. 3 times/wk) and IVIg (0.5 g/kg i.v. every 15 d) for.4 months, while the second @entity1 received the same therapy for 12 and 7 months, respectively. @entity75 was observed after 3 months of therapy in the first @entity1 and after 7 months of therapy in the second @entity1 , as assessed by CT scan. @entity1071 remains in remission 47 and 33 months after therapy, respectively. Our preliminary results suggest that the combination of @entity13089 and IVIg can be an effective therapy for @entity1071 which does not respond to reduction of immunosuppression.

Successful treatment of XXXX with interferon-alpha and intravenous immunoglobulin.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1071 :: ('MESH:D008232', 'Disease') :: ['post-transplant lymphoproliferative disorder', 'PTLD'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine'] @entity75 :: ('MESH:D001927', 'Disease') :: ['Complete disappearance of all lesions'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity13089 :: ('3451', 'Gene') :: ['INF-alpha', 'INF-a'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']
@entity1071 :: (MESH:D008232,Disease) :: ['post-transplant lymphoproliferative disorder']
